Neuspera’s SNM implant comprises a micro-implant that delivers neurostimulation therapy through a wireless platform, including a wearable transmitter and iPad-based clinician programmer. Image Credit: H_Ko / Shutterstock.

Neuspera Medical has announced that its implantable sacral neuromodulation (SNM) system for treating urinary urge incontinence has met the primary endpoint of the device trial.

The US-based company plans to use the data to file for regulatory approval with the US Food and Drug Administration (FDA). Neuspera is seeking approval to use its SNM implant to treat overactive bladder symptoms, especially urinary urge incontinence.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The SANS-UUI multi-centre, single-arm clinical study was designed to demonstrate the safety and efficacy of the SNM implant. The participants received stimulation two hours a day for six months. The trial met its primary endpoint of improving symptoms of urge urinary incontinence at six months.

Neuspera’s SNM implant comprises a micro-implant that delivers neurostimulation therapy through a wireless platform, including a wearable transmitter and iPad-based clinician programmer. The SNM system is implanted in a single procedure and is wirelessly powered via an external device for short daily durations.

Earlier this month, the company raised $23m in Series D financing to fund the premarket approval of the SNM implant and it was cleared by the FDA as a peripheral nerve stimulation (PNS) device to treat chronic pain in April.

Most urinary incontinence devices are developed to treat stress incontinence. UroMems is trialling an implantable device, MyoElectroMechanical, for managing stress urinary incontinence in both men and women. The device is placed around the urethral duct and automatically changes the sphincter opening by pressure adjustments based on the patient’s activity.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In February, Pelvital published the results from a study of its Flyte device to treat women with SUI and weakened pelvic floor muscles. The trial enrolled 119 participants, and 71% of these achieved dry or near dry over two to 12 weeks. After two years, all respondents maintained the improvement in quality of life.